Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

Advanced therapy medicinal products (ATMPs) are highly innovative therapies. Their costs and uncertain value  claims have raised concerns among health technology assessment (HTA) bodies and payers. Little is known about how underlying considerations in HTA of ATMPs shape assessment and reimbursement recommendations. We aim to identify and assess key considerations that played a role in HTA of ATMPs unde rlying reimbursement recommendations.

Source: Value in Health - December 10, 2021 Category: International Medicine & Public Health Authors: Renske M.T. ten Ham, Geert W.J. Frederix, Oliva Wu, Wim Goettsch, Hubert G.M. Leufkens, Olaf H. Klungel, Jarno Hoekman Tags: Comparative-Effectiveness Research Source Type: research